Skip to content

Evaluation of Power Doppler US Technique for the Diagnosis of Spondylarthropathy

Evaluation of Power Doppler US Technique for the Diagnosis of Spondylarthropathy in Patients With Uncertain Diagnosis Consulting for Clinical Symptoms Suggestive of Spondylarthropathy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00794404
Acronym
EchoSpA
Enrollment
489
Registered
2008-11-20
Start date
2004-12-31
Completion date
2010-12-31
Last updated
2016-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing Spondyloarthitis, Spondylarthropathy, Spondyloarthritis

Brief summary

The purpose of this study is to evaluate the interest of enthesis sonography for the diagnosis of spondylarthritis, in patients with uncertain diagnosis consulting for clinical symptoms suggestive of spondylarthritis

Detailed description

Spondylarthritis (SPA) are the second most frequent inflammatory rheumatic disorders and, because it starts early in life and has a chronic progressive course, the impact of this disease on health resources and patient's life quality can be important. Because the characteritic signs of SPA, like radiological evidence of sacro-iliitis, appear late in time, the lag time between the onset first signs of SPA for the patient and the confirmed diagnosis can be very long (up to 8 years). Previous studies proved that patients who are affected by SPA are showing abnormal vascularization of peripheral enthesis more frequently than patients affected by other rheumatic diseases. Ultrasonography in B mode combined with power Doppler (PDUS) is a non invasive and highly sensitive toll which can detect enthesitis and abnormal vsacularization even for the patients who are not showing yet the evidence of SPA's symptomatology. Using PDUS as a early diagnosis tool could lead to the improvement of diagnostic procedures and therapeutic management of SpA and reduce the cost of diagnosis for patient and health insurances.

Interventions

None listed

Sponsors

Groupe Français d'Etude Génétique des Spondylarthropathies
CollaboratorOTHER
French Society of Rheumatology
CollaboratorOTHER
Dr Maria-Atonietta D'AGOSTINO
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients \< 50 years old, consulting for spinal inflammatory symptoms \> 3 months duration * patients consulting for arthritis or tenderness joints \> 3 months duration * patients \< 50 years old consulting for enthesitis or dactylitis \> 3 months duration * patients with uveitis and HLA-B27 positivity * relatives of SpA patients consulting for symptoms suggestive of SpA

Exclusion criteria

* patient with confirmed diagnosis of rheumatic disease (included SpA) * patient protected by law (patient \<18 years old, pregnant woman) * patient who can't atempt the RMI * patient who will have difficulties to complete the two years of follow-up

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026